Quantcast
Channel: WN.com - Articles related to Preclinical Data of Xencor's XmAb Bispecific Technology to be Presented at Upcoming ASH Annual Meeting
Viewing all articles
Browse latest Browse all 614

Celldex Presents Varlilumab Mechanism Data at SITC Annual Meeting 2015

$
0
0
-- Preclinical data suggest cancers vary in sensitivity to mechanisms of CD27 immune modulation -- -- Clinical experience with varlilumab is consistent with immune co-stimulation and regulatory T cell depletion mechanisms, a potential unique benefit for varlilumab -- -- Multiple Phase 1/2 varlilumab combination studies currently ongoing -- HAMPTON, N.J., Nov. 6, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented new preclinical data on varlilumab, a fully human monoclonal agonist antibody that binds and activates CD27, a critical co-stimulatory molecule in the immune activation cascade. Results suggest that cancers may respond to CD27 immune modulation by...

Viewing all articles
Browse latest Browse all 614

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>